In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Goodbye, Blue Sky: Shortcutting Discovery

Executive Summary

A handful of European biotechnology companies is embracing development shortcuts that were once the exclusive provenance of specialty pharmaceutical firms. Shedding traditional biotech start-up discovery models, these firms aim to identify, reformulate and incrementally improve existing products. The hope is that low risk needn't be low reward; in the process these so-called reprofilers of existing therapies may indeed spark an increase in industry productivity. The trick, observers say, is finding and getting their hands on the right products.
Advertisement

Related Content

Solvay Pharma: Dealing Its Way Into the Limelight
Exploiting Connections and Navigating Bumps Along the Brain-Gut Axis
The Anti-Global, Specialist Strategy: Why Bayer's Choice Might Be Right for Other Pharmas
Sinclair Pharma: How Low Risk Can You Go?
Arachnova: The Patent Problem with Re-Indication Strategies
Strakan: Refining Search & Development
Speedel Group: Strings Attached? No Problem
Actelion: A Model for European Biotech
The New Pharmaceutical Sciences
Memories: Ditching De Novo Discovery

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004798

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel